Literature DB >> 16377270

Potential predictive factors of osteoporosis in HIV-positive subjects.

Alfonso Fausto1, Marco Bongiovanni, Paola Cicconi, Laura Menicagli, Emanuela Valentina Ligabò, Sara Melzi, Teresa Bini, Francesco Sardanelli, GianPaolo Cornalba, Antonella d'Arminio Monforte.   

Abstract

Recent reports showed a high frequency of osteopenia/osteoporosis in HIV-infected subjects. Mechanism on the basis of this alteration is still unclear, as the direct effect of virus or of antiretroviral drugs. One hundred sixty-one consecutive HIV-infected outpatients aged 30-50 years, both naive and HAART-treated for >1 year, were included. An interview questionnaire was performed to establish prior pathological, toxic, epidemiological histories, medications intake, physical activity and eating habits. Blood and urinary tests were checked to exclude concomitant diseases, as were markers of bone metabolism and vitamin D3-metabolites. Each subject underwent to a lumbar spine and left hipbone mineral density by DEXA, using WHO criteria for diagnosis of osteopenia/osteoporosis. Radiologist was unaware if the subject was receiving HAART or not. For groups' homogeneity Chi-square, Fisher's exact and Student's t tests were used. Logistic regression analysis was used to find predictors of osteopenia/osteoporosis and linear regression model to find differences in bone mass density. The demographic characteristics of the 48 naive subjects and the 113 on HAART were comparable. Eighty subjects (49.7%) showed osteopenia/osteoporosis: 22 (45.8%) naive and 58 (51.3%) on HAART (P = 0.46). Independent predictors of osteopenia/osteoporosis were female gender (OR: 3.02, 95% CI: 1.26-7.25, P = 0.01 vs. male), older age (OR: 1.10, 95% CI: 1.01-1.20, P = 0.03, for each additional year), low body mass index (OR: 0.78, 95% CI: 0.68-0.91, P = 0.001 for each additional unit) and higher HIV-RNA levels at DEXA (OR: 1.97, 95% CI: 1.16-3.34, P = 0.01 for each additional Log(10)), whereas the use of HAART (OR: 2.61, 95% CI: 0.66-10.27, P = 0.17 vs. naive) and the alterations of markers of bone metabolism were not significantly related to osteopenia/osteoporosis. Similar findings were obtained using linear regression model analysis. HIV-infected subjects have a high frequency of osteopenia/osteoporosis. Traditional risk factors are predictive of osteopenia/osteoporosis also in HIV-subjects; the association with higher HIV-RNA levels can suggest a direct role of HIV itself in the occurrence of bone disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16377270     DOI: 10.1016/j.bone.2005.11.001

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  36 in total

1.  Bone disease in HIV infection.

Authors:  Maristella Francesca Saccomanno; Adriana Ammassari
Journal:  Clin Cases Miner Bone Metab       Date:  2011-01

Review 2.  A challenge for the future: aging and HIV infection.

Authors:  Tammy M Rickabaugh; Beth D Jamieson
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

Review 3.  Care of the human immunodeficiency virus-infected menopausal woman.

Authors:  Helen Elizabeth Cejtin
Journal:  Am J Obstet Gynecol       Date:  2011-12-30       Impact factor: 8.661

4.  Implications of Immune Checkpoint Expression During Aging in HIV-Infected People on Antiretroviral Therapy.

Authors:  Lesley R de Armas; Suresh Pallikkuth; Stefano Rinaldi; Rajendra Pahwa; Savita Pahwa
Journal:  AIDS Res Hum Retroviruses       Date:  2019 Nov/Dec       Impact factor: 2.205

Review 5.  Gynecologic issues in the HIV-infected woman.

Authors:  Helen E Cejtin
Journal:  Infect Dis Clin North Am       Date:  2008-12       Impact factor: 5.982

6.  Bone effects of rosiglitazone in HIV-infected patients with lipoatrophy.

Authors:  Allison C Ross; Corrilynn O Hileman; Todd T Brown; Neal Fedarko; Norma Storer; Danielle Labbato; Grace A McComsey
Journal:  HIV Clin Trials       Date:  2012 Jul-Aug

Review 7.  Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease.

Authors:  Erdembileg Anuurad; Alison Semrad; Lars Berglund
Journal:  Metab Syndr Relat Disord       Date:  2009-10       Impact factor: 1.894

8.  Risk factors for decreased bone density and effects of HIV on bone in the elderly.

Authors:  S Jones; D Restrepo; A Kasowitz; D Korenstein; S Wallenstein; A Schneider; M J Keller
Journal:  Osteoporos Int       Date:  2007-12-11       Impact factor: 4.507

9.  Continuous antiretroviral therapy decreases bone mineral density.

Authors:  Birgit Grund; Grace Peng; Cynthia L Gibert; Jennifer F Hoy; Rachel L Isaksson; Judith C Shlay; Esteban Martinez; Peter Reiss; Fehmida Visnegarwala; Andrew D Carr
Journal:  AIDS       Date:  2009-07-31       Impact factor: 4.177

10.  Role of bone mineral density in predicting morphometric vertebral fractures in patients with HIV infection.

Authors:  T Porcelli; D Gotti; A Cristiano; F Maffezzoni; G Mazziotti; E Focà; F Castelli; A Giustina; E Quiros-Roldan
Journal:  Osteoporos Int       Date:  2014-07-24       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.